Company intelligence / Profile preview

RPH Pharmaceuticals

Ownership: Private
Development stage: Commercial

Overview

RPH Pharmaceuticals manages intellectual property and develops generic and specialty pharmaceuticals for Recipharm, with focus on various dosage forms including solid, liquid, lyophilized, hormonal, and inhalation products. It has filed applications for infectious disease drug products in Europe in collaboration with partners such as Astimex Pharma AB. Most products are generics and not innovative NCEs.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

betamethasone

Commercial

Indications: Inflammation

3 more assets in the full pipeline.

Request access →

Partnerships

Astimex Pharma

Beyond the preview

Go deeper on RPH Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPH Pharmaceuticals.

Explore the full profile